Biofrontera Inc./$BFRI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Biofrontera Inc.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions.
Ticker
$BFRI
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
93
ISIN
US09077D2099
Website
Biofrontera Inc. Metrics
BasicAdvanced
$5.7M
-
-$1.69
0.38
-
Price and volume
Market cap
$5.7M
Beta
0.38
52-week high
$1.10
52-week low
$0.54
Average daily volume
206K
Financial strength
Current ratio
1.399
Quick ratio
0.531
Long term debt to equity
946.055
Total debt to equity
1,036.887
Interest coverage (TTM)
-19.89%
Profitability
EBITDA (TTM)
-15.968
Gross margin (TTM)
53.26%
Net profit margin (TTM)
-30.33%
Operating margin (TTM)
-42.87%
Effective tax rate (TTM)
-0.17%
Revenue per employee (TTM)
$410,000
Management effectiveness
Return on assets (TTM)
-49.47%
Return on equity (TTM)
1,673.93%
Valuation
Price to revenue (TTM)
0.108
Price to book
11.38
Price to tangible book (TTM)
12.19
Price to free cash flow (TTM)
-0.371
Free cash flow yield (TTM)
-269.41%
Free cash flow per share (TTM)
-162.08%
Growth
Revenue change (TTM)
14.28%
Earnings per share change (TTM)
-84.52%
3-year revenue growth (CAGR)
9.29%
3-year earnings per share growth (CAGR)
-68.06%
Biofrontera Inc. News
AllArticlesVideos
Biofrontera Inc. Announces Major Restructuring of Relationship With Biofrontera AG Backed By $11 Million Investment
GlobeNewsWire·4 hours ago
BIOFRONTERA INC. IS NEGOTIATING FUNDAMENTAL CHANGES TO ITS COOPERATION WITH BIOFRONTERA AG
GlobeNewsWire·3 weeks ago
Biofrontera Inc. Announces Patent for Propylene Glycol-Free Formula of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Now Listed in FDA Orange Book
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Biofrontera Inc. stock?
Biofrontera Inc. (BFRI) has a market cap of $5.7M as of June 30, 2025.
What is the P/E ratio for Biofrontera Inc. stock?
The price to earnings (P/E) ratio for Biofrontera Inc. (BFRI) stock is 0 as of June 30, 2025.
Does Biofrontera Inc. stock pay dividends?
No, Biofrontera Inc. (BFRI) stock does not pay dividends to its shareholders as of June 30, 2025.
When is the next Biofrontera Inc. dividend payment date?
Biofrontera Inc. (BFRI) stock does not pay dividends to its shareholders.
What is the beta indicator for Biofrontera Inc.?
Biofrontera Inc. (BFRI) has a beta rating of 0.38. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.